Vaere Robert J De Net Worth

The estimated Net Worth of Vaere Robert J De is at least $18.8 Milion dollars as of 30 September 2014. Vaere De owns over 51,942 units of Horizon Therapeutics Plc stock worth over $17,969,978 and over the last 13 years Vaere sold HZNP stock worth over $853,762.

Vaere De HZNP stock SEC Form 4 insiders trading

Vaere has made over 5 trades of the Horizon Therapeutics Plc stock since 2012, according to the Form 4 filled with the SEC. Most recently Vaere sold 51,942 units of HZNP stock worth $637,848 on 30 September 2014.

The largest trade Vaere's ever made was selling 51,942 units of Horizon Therapeutics Plc stock on 30 September 2014 worth over $637,848. On average, Vaere trades about 9,258 units every 60 days since 2011. As of 30 September 2014 Vaere still owns at least 154,514 units of Horizon Therapeutics Plc stock.

You can see the complete history of Vaere De stock trades at the bottom of the page.

What's Vaere De's mailing address?

Vaere's mailing address filed with the SEC is C/O HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD, IL, 60015.

Insiders trading at Horizon Therapeutics Plc

Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... a Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.

What does Horizon Therapeutics Plc do?

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Complete history of Vaere De stock trades at Horizon Therapeutics Plc

Horizon Therapeutics Plc executives and stock owners

Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:

• Timothy Walbert,
  Chairman of the Board, President, Chief Executive Officer
• Timothy P. Walbert,
  Chairman, Pres & CEO
• Barry Moze,
  Executive Vice President, Chief Administrative Officer
• Paul Hoelscher,
  Chief Financial Officer, Executive Vice President
• Vikram Karnani,
  Executive Vice President, President - International
• Paul W. Hoelscher,
  Exec. VP & CFO
• Andy Pasternak,
  Exec. VP & Chief Strategy Officer
• Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
  Exec. VP & Chief Medical Officer
• Michael Grey,
  Lead Independent Director
• Jeffrey Himawan,
  Independent Director
• H. Thomas Watkins,
  Independent Director
• James Shannon,
  Independent Director
• William Daniel,
  Independent Director
• Pascale Witz,
  Independent Director
• Susan Mahony,
  Independent Director
• Irina Konstantinovsky,
  Chief Human Resource Officer, Executive Vice President
• Daniel Camardo,
  Executive Vice President, President - U.S.
• Jeffrey Kent,
  Senior Vice President, Head of Medical Affairs and Outcomes Research
• Andy Pasternak,
  Executive Vice President, Chief Business Officer
• Geoffrey Curtis,
  Executive Vice President - Corporate Affairs, Chief Communications Officer
• Tina Ventura,
  Senior Vice President, Investor Relations
• Michael DesJardin,
  Executive Vice President - Technical Operations and Corporate Quality
• Brian Beeler,
  Executive Vice President, General Counsel
• Aaron L. Cox,
  Exec. VP of Fin. & CFO
• Jane Gonnerman,
  Group VP of Corp. Devel., Chief of Staff & Office of the CEO
• Geoffrey M. Curtis,
  Exec. VP of Corp. Affairs & Chief Communications Officer
• Sean M. Clayton J.D.,
  Exec. VP & Gen. Counsel
• Timothy Ayers,
  Chief Compliance Officer & VP
• Dr. Karin Rosen M.D., Ph.D.,
  Exec. VP of R&D and Chief Scientific Officer
• Miles W. McHugh,
  Chief Accounting Officer & Sr. VP
• Robert Carey,
  EVP & Chief Business Officer
• Jeff Himawan,
  Director
• Gino Santini,
  Director
• Timothy J. Ackerman,
  SVP, Commercial Operations
• Miles W Mc Hugh,
  Sr VP & Princ. Acctg Officer
• George P Hampton,
  See remarks
• Virinder Nohria,
  Director
• Ronald Pauli,
  Director
• Vaere Robert J De,
  EVP & CFO
• Therapeutics Holdings Llc V...,
  10% owner
• Todd N Smith,
  SVP, Marketing & Alliance Mgmt
• David Happel,
  EVP, Commercial Dev & Strategy
• Eric Mosbrooker,
  SVP, Orphan Business Unit
• Shao Lee Lin,
  EVP, Head of R&D and CSO
• Jeff Kent,
  See remarks
• Jeffrey W Bird,
  Director
• Michael Adatto,
  Senior VP Sales & Managed Care
• Bio Ventures Ii Lp Quaker,
  10% owner
• Venture Fund Vi Lp Atlas Ve...,
  
• Peter Johann,
  Director
• Jean Francois Formela,
  Director
• Venture Fund Vi Lp Atlas Ve...,
  
• Woodlands Health Ventures F...,
  10% owner
• Louis C Bock,
  Director
• Hubert Birner,
  Director
• John B Thomas,
  EVP, Corporate Strategy and IR
• David George Kelly,
  EVP, Company Secretary
• John J Kody,
  EVP, Chief Commercial Officer
• Balaji Venkataraman,
  
• Aaron Cox,
  EVP, Chief Financial Officer
• Jeffrey W Sherman,
  EVP and Chief Medical Officer
• Karin Rosen,
  EVP, R&D & CSO
• Elizabeth H.Z. Thompson,
  EVP, Research & Development
• Sean M. Clayton,
  EVP, General Counsel
• Jacopo Leonardi,
  Pres., Global Commercial Ops
• Patrick Mc Ilvenny,
  Chief Accounting Officer